Cue Health

Cue Health, Inc. is a healthcare technology company that puts consumers in control of their health information and places diagnostic information at the center of care. It enables people to manage their health through real-time, actionable, and connected health information, offering individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime, in a device that fits in the palm of the hand. The firms first-of-its-kind COVID-19 test was the first FDA-authorized molecular diagnostic test for at-home and over-the-counter use without a prescription and physician supervision. The company was founded by Ayub Khattak and Clint Sever in 2010 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Nobilis Health Corp. engages in the operation and development of outpatient surgery centers. The firm owns and manages ambulatory and acute care facilities to deliver innovative surgical services. It operates through Medical Services and Marketing Services segment. The Medical Services segment provides the operation of hospitals, outpatient facilities, and other various related health care services. The Marketing Services segment provides marketing services, patient education services, and patient care coordination management services. The company was founded on March 16, 2007 and is headquartered in Houston, TX.

Cue Health (NASDAQ: HLTH ) stock is up on Thursday despite the healthcare technology company recently announcing plans to wind down its business. Cue Health revealed earlier this week that it's closing up shop with its Chapter 7 bankruptcy relief filing.

Why Is Cue Health (HLTH) Stock Up 99% Today?

Cue Health (NASDAQ: HLTH ) stock is down on Wednesday after the healthcare technology company announced plans to wind down its business. According to a press release from Cue Health, the company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code to pursue this wind-down.

Why Is Cue Health (HLTH) Stock Down 40% Today?

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced the Company has filed voluntary petitions under Chapter 7 of the U.S. Bankruptcy Code in the District of Delaware to pursue a wind down of its business. Cue has been working diligently to strengthen the Company's financial foundation, including taking a number of actions to reduce costs and improve operational efficiency. Cue also undertook an extensive process t.

Cue Health to Pursue Wind Down of the Business

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (Nasdaq: HLTH), a healthcare technology company (the “Company”), has received a warning letter from the FDA about its Emergency Use Authorized (EUA) COVID-19 test. The Company is currently evaluating the letter and determining its response, with more information to follow in the next few days. About Cue Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that empowers healthcare providers to streamline their ability to deliver value-base.

Cue Health Evaluating Warning Letter Received from Food and Drug Administration (FDA)

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its first quarter 2024 financial results on Monday, May 13, 2024. The company will not be hosting a conference call. About Cue Health Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. Cue's platform offers individuals and healthcare providers convenient and per.

Cue Health to Announce First Quarter Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today announced strategic actions implemented by its Board of Directors (the “Board”) to best position the Company for its next stage: Clint Sever, co-founder and current Chief Product Officer, has been appointed CEO, effective immediately. Sever succeeds Ayub Khattak, who is stepping down as Chief Executive Officer, President, and Chairman. Khattak will remain a member of the B.

Cue Health Announces Strategic Actions to Position Company for Next Stage

Nutex Health Inc

Americas Silver

Listen, if you haven't gotten the memo, penny stocks are incredibly dangerous. Yes, they're cheap – in this case, extremely cheap.

3 Promising Penny Stocks You Can Pick Up for Less Than a Quarter

Cue Health, Inc. (HLTH) Q4 2023 Earnings Call Transcript

Cue Health Inc. (HLTH) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.50 per share a year ago.

Cue Health Inc. (HLTH) Reports Q4 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue" or the “Company”) (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the fourth quarter and full-year 2023. Recent Highlights Reported fourth quarter total revenue of $18.8 million. Full-year 2023 total revenue was $70.9 million Submitted additional clinical samples and stability data for RSV to the FDA in support of de novo submission Submitted additional clinical samples and gathering additional stability da.

Cue Health Reports Fourth Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its fourth quarter and full year 2023 financial results on Wednesday, March 13, 2024. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link h.

Cue Health to Announce Fourth Quarter and Full Year 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced it entered into a cooperation agreement (the “Cooperation Agreement”) with Tarsadia Investments (“Tarsadia”), and appointed Rishi Reddy to its board of directors (the “Board”), effective immediately. Mr. Reddy is a Managing Director at Tarsadia, where he leads the firm's venture and growth equity strategy. He was previously an Observer on Cue's Board of Directors from April 2018 to September.

Cue Health Announces Appointment of Rishi Reddy to Board of Directors

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Tuesday, February 13, 2024. About Cue Health Cue Health Inc. (Nasdaq: HLTH) is a healthcare technology company that uses diagnostic-enabled care to empower people to live their healthiest lives. The Cue Health platform offers individuals and healthcare provid.

Cue Health to Participate at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Cue Health Inc. (NASDAQ:HLTH ) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Lorna Williams - Investor Relations Ayub Khattak - Chairman, President and Chief Executive Officer Aasim Javed - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Operator Good day and thank you for standing by. Welcome to the Cue Health Third Quarter 2023 Earnings Conference Call.

Cue Health Inc. (HLTH) Q3 2023 Earnings Call Transcript

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the third quarter 2023. Recent Highlights Reported third quarter total revenue of $17.5 million, approximately 50% above the midpoint of our guidance range of $11 to $13 million. Three tests in review with the FDA: Cue® Flu A/B + COVID-19 Multiplex Molecular Test Emergency Use Authorization (EUA) for at-home and point-of-care use. Cue Flu A/B Molecular Tests.

Cue Health Reports Third Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that it will release its third quarter 2023 financial results on Wednesday, November 8, 2023. In conjunction with the release, Cue will host a conference call and webcast that day at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss its financial results and recent highlights. To access the live call via telephone, please register in advance using the link here. Upon reg.

Cue Health to Announce Third Quarter 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Kelly Day and other concerned stockholders sent a letter to the board of directors of Cue Health outlining their urgent concerns for the Company.

Concerned Stockholders of Cue Health Send Letter to Board

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, announced today the peer-reviewed publication of an independent clinical study - the largest of its kind on asymptomatic people - finding that Cue's molecular COVID-19 test provides comparable accuracy to centralized lab-based RT-PCR with the advantages of convenient use at the point-of-care or home settings and fast results in 20 minutes. The study, published in Microbiology Spectrum, a journal produced by.

Peer-Reviewed Independent Study Published in Microbiology Spectrum Finds Cue Health's Molecular COVID-19 Test is as Accurate as a Lab-Based PCR Test

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that its Board of Directors has unanimously approved the adoption of a limited-duration shareholder rights plan (the “Rights Plan”) to protect the long-term interests of all shareholders. The Board adopted the Rights Plan in response to a rapid accumulation of shares by a third party. The Rights Plan is effective immediately and has a one-year term, expiring on September 20, 2024. “Cue is com.

Cue Health Adopts Limited-Duration Shareholder Rights Plan

NEW YORK--(BUSINESS WIRE)--Tarsadia Investments, LLC (“Tarsadia”) represents long-term stockholders of Cue Health, Inc. (the “Company” or “Cue”) (NASDAQ: HLTH), with holdings that collectively make them a top 10 stockholder. Today, Tarsadia sent an open letter to the board of directors of Cue (the “Board”) highlighting the urgent need for the Board to act. Commenting on the letter and the Company's dire situation, Tarsadia said: "We have been investors in Cue Health for over 5 years and are str.

Tarsadia Investments Sends Letter to Board of Cue Health, Inc.

SAN DIEGO--(BUSINESS WIRE)--Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, announced today that its management team will present at the following investor conferences: 2023 Wells Fargo Healthcare Conference Presenting via fireside chat on Wednesday, September 6, 2023 at 3:00 p.m. Eastern Time in Boston, MA at the Encore Boston Harbor Morgan Stanley 21st Annual Global Healthcare Conference Presenting via fireside chat on Monday, September 11, 2023 at 2:55 p.m. Eastern Time i.

Cue Health to Present at Upcoming Investor Conferences

Cue Health Inc. (NASDAQ:HLTH ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Lorna Williams - IR Ayub Khattak - Co-Founder, President, CEO & Chairman Aasim Javed - CFO Conference Call Participants David Delahunt - Goldman Sachs Charles Rhyee - TD Cowen Operator Good day and thank you for standing by. Welcome to the Cue Health Second Quarter 2023 Earnings Conference Call.

Cue Health Inc. (HLTH) Q2 2023 Earnings Call Transcript

Cue Health Inc. (HLTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.53. This compares to loss of $0.37 per share a year ago.

Cue Health Inc. (HLTH) Reports Q2 Loss, Tops Revenue Estimates

SAN DIEGO--(BUSINESS WIRE)--Cue Health Inc. ("Cue") (Nasdaq: HLTH), a healthcare technology company, today reported financial results for the second quarter 2023. Recent Highlights Reported second quarter total revenue of $10 million at the top-end of our guidance. Received landmark first, over-the-counter De Novo authorization from the FDA for the Cue COVID-19 Molecular Test. Awarded a new $28.3 million contract from BARDA, the U.S. Biomedical Advanced Research and Development Authority, to ac.

Cue Health Reports Second Quarter 2023 Financial Results

SAN DIEGO--(BUSINESS WIRE)--Cue Health (Nasdaq: HLTH), a healthcare technology company, today announced that it has been awarded a new approximately $28 million contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services (HHS), to develop a Flu A/B, RSV, and COVID-19 molecular multiplex test for both over-the-counter (OTC) and point-of-care (POC) use. Cu.

Cue Health Awarded New $28 Million Federal Contract to Develop Flu A/B, RSV, COVID-19 Molecular Multiplex Test for Both Over-the-Counter and Point-of-Care Use

News for Cue Health Stock (HLTH)